Valuation: Exelixis, Inc.

Market Cap 14.11B 12.36B 11.46B 10.54B 19.88B 1,359B 20.12B 137B 53.5B 666B 52.95B 51.81B 2,299B P/E 2026 *
17.6x
P/E 2027 * 15.1x
Enterprise Value 13.33B 11.69B 10.83B 9.97B 18.79B 1,284B 19.02B 129B 50.57B 629B 50.05B 48.97B 2,173B EV / Sales 2026 *
5.13x
EV / Sales 2027 * 4.23x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day+1.06%
1 week+0.63%
Current month+3.14%
1 month+8.11%
3 months+22.29%
6 months+25.24%
Current year+28.04%
1 week 54.75
Extreme 54.7501
56.75
1 month 50.88
Extreme 50.88
57.57
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 8.58
Extreme 8.58
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
5/27/26 Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%+0.63%+26.80%+185.02% 14.11B
+1.80%-0.83%+52.79%+86.50% 55.57B
-0.37%+0.91%+55.56%+58.15% 54.26B
+0.18%+2.13%-15.22%-14.97% 23.35B
+1.50%-1.35%+5.68%+415.28% 23.54B
+0.05%-1.77%+38.71%-4.22% 20.32B
+0.65%-1.37%+35.02%-30.59% 17.36B
+1.08%-3.63%+36.77%+547.87% 15.59B
0.00%-2.08%+165.40%+297.92% 14.96B
+2.07%+1.85%+65.22%+153.44% 12.61B
Average +0.80%-0.78%+46.67%+169.44% 25.17B
Weighted average by Cap. +0.75%-1.06%+45.17%+136.36%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.11B 1.94B 3.66B 250B 3.71B 25.19B 9.86B 123B 9.76B 9.55B 424B 2.93B 2.56B 2.38B 2.19B 4.12B 282B 4.17B 28.36B 11.1B 138B 10.98B 10.75B 477B
Net income 812M 712M 659M 607M 1.14B 78.2B 1.16B 7.87B 3.08B 38.32B 3.05B 2.98B 132B 942M 826M 765M 704M 1.33B 90.74B 1.34B 9.13B 3.57B 44.47B 3.54B 3.46B 154B
Net Debt -774M -678M -628M -578M -1.09B -74.52B -1.1B -7.5B -2.93B -36.52B -2.9B -2.84B -126B -1.72B -1.5B -1.39B -1.28B -2.42B -165B -2.45B -16.63B -6.51B -81B -6.44B -6.3B -280B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-07-21 US$56.12 +1.06% 1,820,120
26-07-20 US$55.53 -0.70% 2,381,658
26-07-17 US$55.92 +0.43% 2,555,561
26-07-16 US$55.68 +0.23% 2,031,019
26-07-15 US$55.55 -0.39% 1,895,909
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
56.12USD
Average target price
50.93USD
Spread / Average Target
-9.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock